Prostate adenocarcinoma grade group 1: Rationale for retaining a cancer label in the 2022 World Health Organization classification

Abstract

We present the rationale for keeping the "cancer" label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.

Journal details

Pages Epub ahead of print
Available online
Publication date

Crick authors

Crick First author
Crick Corresponding author